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Abstract
The hypothesis that the S allele of the 5-HTTLPR serotonin transporter promoter region is 
associated with increased risk of depression, but only in individuals exposed to stressful situations, 
has generated much interest, research, and controversy since first proposed in 2003. Multiple 
meta-analyses combining results from heterogeneous analyses have not settled the issue. To 
determine the magnitude of the interaction and the conditions under which it might be observed, 
we performed new analyses on 31 datasets containing 38 802 European-ancestry subjects 
genotyped for 5-HTTLPR and assessed for depression and childhood maltreatment or other 
stressful life events, and meta-analyzed the results. Analyses targeted two stressors (narrow, broad) 
and two depression outcomes (current, lifetime). All groups that published on this topic prior to 
the initiation of our study and met the assessment and sample size criteria were invited to 
participate. Additional groups, identified by consortium members or self-identified in response to 
our protocol (published prior to the start of analysis1) with qualifying unpublished data were also 
invited to participate. A uniform data analysis script implementing the protocol was executed by 
each of the consortium members. Our findings do not support the interaction hypothesis. We found 
no subgroups or variable definitions for which an interaction between stress and 5-HTTLPR 
genotype was statistically significant. In contrast, our findings for the main effects of life stressors 
(strong risk factor) and 5-HTTLPR genotype (no impact on risk) are strikingly consistent across 
our contributing studies, the original study reporting the interaction, and subsequent meta-
analyses. Our conclusion is that if an interaction exists in which the S allele of 5-HTTLPR 
increases risk of depression only in stressed individuals, then it is not broadly generalizable, but 
must be of modest effect size and only observable in limited situations.
INTRODUCTION
Depression negatively impacts health more than any other chronic disease2 and is a leading 
cause of total disease burden worldwide.3 Both genetic and environmental factors influence 
depression;4 research on the etiology of depression suggests substantial heritability of 40–
50%.4–9 Only recently have genome-wide association studies (GWAS) begun to identify and 
replicate specific loci associated with depression.10–12 The findings from these studies 
suggest that (1) the effects of individual single nucleotide polymorphisms (SNPs) on major 
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depressive disorder (MDD) are small in magnitude (requiring large sample sizes to detect), 
and (2) candidate genes generally do not show evidence of association in either GWAS or 
subsequent large-scale meta-analyses.13 Gene-environment interactions (G×E) (e.g., genetic 
variants whose influence on depression risk is only seen under specific environmental 
exposures) are one mechanism that may contribute to the complexity of identifying genetic 
associations with depression.14, 15
A high profile report of a G×E effect on the development of depression involves an 
interaction between stressful life events and a functional, repeat length polymorphism (5-
HTTLPR) in the promoter region of the serotonin transporter gene (SLC6A4) on 
chromosome 17.16 SLC6A4 encodes an integral membrane protein that transports the 
neurotransmitter serotonin from synaptic spaces into presynaptic neurons. The short (S) 
allele of 5-HTTLPR is associated with less transcription of the serotonin transporter 
compared to the long (L) allele.17, 18 The report found that carriers of either one or two 
copies of the S allele of 5-HTTLPR were more likely to develop major depressive disorder, 
increased depressive symptoms, and suicidality in response to childhood maltreatment or 
other stressful life events than were individuals homozygous for the L allele. Furthermore, 
there was evidence of a dose-response relationship, with risk of depression higher amongst 
those with two copies of the S allele compared to individuals with only one copy in the 
presence of stress. This G×E interaction report has had considerable influence on the field; it 
has been cited over 4000 times and over one hundred publications have investigated the 
combined impact of 5-HTTLPR variation and stress on risk for depression.
However, controversy over the robustness of this G×E interaction continues. Although it is 
likely that G×E interactions play an important role in disease, gene-by-environment studies 
are challenged by the fact that statistical power to detect interactions is typically less than for 
main effects.19 Furthermore, many candidate gene main-effect association reports appear to 
be false positives.20, 21 As Duncan and Keller22 illustrate, this indicates a need for caution 
regarding similar gene-by-environment hypotheses. Several meta-analyses have examined 
the 5-HTTLPR-by-stress hypothesis, some providing support for the interaction and others 
finding no evidence for it,23–26 with various reasons proposed for the differences.22, 25, 27–29 
Munafò et al.24 performed a literature-based meta-analysis, finding that only 5 of the 
previously published studies (N = 2 999) used phenotypes and statistical models suitably 
comparable to the original study to be included in the meta-analysis. This meta-analysis did 
not support replication of the original finding. Risch et al.23 obtained individual level data 
from 10 previously published studies (N= 14 250) that met inclusion criteria and analyzed 
the data using a common model based on number of stressful life events. This re-analysis 
found no evidence for either a main effect or interaction effect of 5-HTTLPR on depression. 
Karg et al.25 (56 studies, N= 40 749) and Sharpley et al.26 (81 studies, N= 54 996) both 
performed literature-based meta-analyses and reported strong evidence for the interaction. 
Karg et al. and Sharpley et al. criticized the previous analyses of Munafò et al. and Risch et 
al. for being too restrictive in their inclusion of studies. The approaches of Karg et al. and 
Sharpley et al., in turn, have been criticized for combining p-values too broadly by allowing 
studies with an opposite direction of effect to supply supportive evidence, by including 
results from studies with incompatible statistical and genetic models, and by including 
outcomes other than depression.22 One key issue contributing to disputes over the 
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appropriateness of the prior reports and meta-analyses is the heterogeneity of the studies.22 
Heterogeneity pervades many key factors in the prior analyses, including measurements of 
depression and stress, genetic ancestry, and statistical models.
The primary objective of the current study was to increase understanding of the role 5-
HTTLPR might play as a moderator of the response to stress as it impacts depression. To 
address the complexities of this topic, we performed a collaborative meta-analysis of data 
available from the participating studies, both published and unpublished, using consistent de 
novo analyses and variables determined a priori as described in the pre-registered protocol.1 
Our collaborative meta-analysis strategy, wherein the consortium worked to harmonize 
phenotypes across studies, to prioritize specific analyses a priori, and to apply identical de 
novo statistical analyses across all participating studies, provided a balance between 
maximizing sample size while minimizing heterogeneity. With this approach and the large 
number of contributing samples, we are well positioned to clarify the relationship between 
5-HTTLPR, stress, and depression.
METHODS
Coordinated meta-analysis process
I. Recruitment of studies—Our goal was to include data from as many pertinent studies 
as possible. However, analyses based on a small number of samples can be statistically 
unstable, a problem that is exacerbated in models involving multiple covariates and an 
interaction term. For these reasons, we required participating studies to have genotyped at 
least 300 individuals for 5-HTTLPR and to have assessed depression and stress for 
inclusion. Our recruitment started with groups that had previously published on this topic 
who met our inclusion criteria. Additional groups, identified through referral by existing 
consortium members and self-referral based on the publication of our protocol, that had not 
published on this topic, but which satisfied the inclusion criteria, were also invited to 
participate. Supplemental Table S1 shows the datasets contributing to this meta-analysis and 
how they relate to the Risch meta-analysis23 based on primary data and the three literature-
based meta-analyses of Munafò, Karg, and Sharpley.24–26 The studies contributing to each 
analysis varied, with no study contributing results for every analysis. Here we cite the 
foundational papers for the published studies that contributed results to the project.30–58
II. Development of the protocol—The consortium developed an analysis protocol that 
focused on data harmonization and analysis prioritization. The decision was made to analyze 
childhood maltreatment as a source of stress separately from other sources of life stress 
because childhood maltreatment was assumed to precede the initial onset of depression and 
to have a significant life-long impact.59–61 Life stressors other than childhood maltreatment 
include such things as physical or sexual assault, experience of life-threatening illness, loss 
of employment, loss of a spouse, or military conscription. When possible, analyses of other 
life stressors included information on the timing of both the stressful events and the 
depression assessment. For both childhood maltreatment and broadly defined stress (defined 
as experiencing either childhood maltreatment or other life stress), we examined histories of 
both lifetime depression and current depression (at the time of assessment). In addition to 
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stress exposure and genotype, sex and age were used as covariates in our analysis models. 
Subjects assessed between the ages of 21 and 30 were of particular interest because of the 
possibility that the effect might be strongest at these ages, which is a similar age range to the 
individuals in the original report.16
All analyses were stratified by genetic ancestry. An outline of the primary analyses can be 
found in Supplemental Table S2 and more detailed descriptions of the planned analyses are 
provided in our published protocol.1 All code and documents relevant for running the 
analyses and meta-analysis are available in the public repository at https://github.com/
achorton/SD_5HTTLPR.
III. Analysis script—The coordinating center at Washington University in St. Louis 
developed data coding instructions (Supplemental Table S3) based on the protocol and wrote 
an analysis script in R.62 Each participating group reformatted their data for the analysis and 
executed the analysis script locally on their own data. Results from these analyses, including 
coefficients and standard errors for the primary and secondary analyses as well as 
demographic information on the data set, were sent to the coordinating center for meta-
analysis.
IV. Quality control assessments
Data coding: To ensure high quality data, the analysis team at Washington University 
examined the submitted results for unusual values (e.g., unexpected allele frequencies, sex 
ratios, stress exposure rates, rates of depression diagnoses, missing values). When unusual 
values were found, the team worked with the data providers to ensure that the final results 
accurately reflected their data.
Poorly fitted models: For results from a study to be included in a particular meta-analysis, 
we required a minimum of 50 individuals to be phenotyped for all variables in the model and 
that the resulting | β | < 10 (corresponding to odds ratios (OR) between 1/20 000 and 20 
000). Of the results that satisfied both the minimum sample size and restriction on β, all of 
the OR for the interaction terms were within the more reasonable range of 1/20 to 20.
V. Meta-analysis—Meta-analyses of both the primary and secondary models were 
performed using the R packages rmeta63 and metafor,64 and SAS.65 Because of the great 
variability of the data sources, all meta-analysis results are based on random effects models 
even though there was little statistical evidence of heterogeneity (see Supplemental Table 
S4).
VI. Models Analyzed—In keeping with the original report,16 we tested the following 
main hypothesis:
The risk of depression displays an interaction between 5-HTTLPR genotype (LL, LS, SS) 
and exposure to stress: namely, the 5-HTTLPR genotype shows no association to depression 
in individuals not exposed to stress, but shows a dose response effect (increased risk for 
more copies of the S allele) in individuals exposed to stress. Our primary genetic coding was 
additive in the number of copies of the S allele. Our template for analysis is in the form
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That is, for a dichotomous depression diagnosis,
Support for the hypothesis that S alleles are associated with an increased risk for depression 
in stress-exposed individuals, but not in individuals who are unexposed to stress, would be 
reflected by an OR > 1 for the gene × stress interaction term. We examined this main 
hypothesis in multiple settings in an attempt to determine a range of conditions under which 
the effect might be found. We examined two types of stress (childhood maltreatment, other 
life stress), two categories of depression (depression during lifetime, current depression), 
and two age ranges (all ages, young adults between the ages of 21 and 30).
Additional secondary hypotheses (e.g., whether there is a main effect of 5-HTTLPR 
variation on depression, whether the effect is observed when using a dominant model (LL vs 
SL or SS), whether the effect would be observed more strongly in a single sex) were also 
examined to improve our understanding of this complex topic.
Our broadest analyses incorporated information from studies that could not evaluate the full 
model (e.g., a study with only female subjects, a study with only stress-exposed subjects). 
These analyses performed logistic regression on pooled genotype counts with contributing 
study coded as a class variable in the model.
We used the results for the sex and stress terms as positive controls because females and 
stress-exposed individuals are known to be at increased risk for depression.
RESULTS
Our participating groups contributed a total of 43 165 total subjects genotyped for 5-
HTTLPR and assessed for depression and childhood maltreatment and/or other stressful life 
events. Of these, 40 693 (94.3%) were of European ancestry, and after harmonization 38 802 
subjects contributed to at least one analysis. The non-European samples were distributed 
across five strata (African, African-European Admixed, Asian, Pacific Islander, and 
Hispanic) and were not meta-analyzed due to small sample size. Supplemental Table S5 
provides key demographic information about the data included in the meta-analyses (e.g., N, 
S allele frequency, frequencies of the key phenotypes). For each of the datasets in Table S5, 
Table S6 lists whether the study design was cross-sectional or longitudinal, the criteria used 
to diagnose depression, and the assessments used to determine childhood maltreatment and 
other stressful life events. Table S7 provides information about additional datasets for which 
the script was run, but whose results could not be included in any of the primary or 
secondary analyses. Further details about each participating study can be found in 
Supplemental Table S8.
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Table 1 lists results from analyses across all age groups based on exposure to our two 
stressors of interest and diagnoses of our two depression outcomes. As expected, our two 
positive control factors, sex (OR < 1, indicating that males are at lower risk) and exposure to 
stress (OR > 1 indicating that exposure to stress increases risk), each have strong, consistent, 
and highly statistically significant associations to diagnoses of depression whether the 
diagnosis was for lifetime depression or current depression at the time of assessment. We do 
not see a main effect association between number of copies of the S allele and depression in 
these analyses, a finding that matches what we would expect from prior reports, including 
the study originally reporting the interaction.16
Importantly, our meta-analyses do not support the hypothesis that in subjects exposed to 
stress, carrying S alleles for 5-HTTLPR confers a differential and increased risk for either 
lifetime or current depression compared to the impact of carrying S alleles in subjects who 
were not exposed to stress. In fact, when the outcome is current depression, the point 
estimates for the interaction terms are all in the direction opposite of the hypothesis.
The broad stress analyses examined stress resulting from either childhood maltreatment or 
other life stress. The other life stress exposure was examined in two ways: including only 
subjects for whom the other life stress was documented to have occurred within the five 
years prior to depression (five years prior to assessment if no depression) or including all 
subjects. The 5-year threshold was chosen to match the original study design of Caspi et al. 
(2003).16 Most of the studies contributing to this set of analyses assessed stress over a 
shorter period, which is more in line with current beliefs about the depressogenic effects of 
acute stressors experienced in adulthood.
Forest plots illustrating how the individual studies contribute to the first meta-analysis in 
Table 1 (outcome: lifetime depression diagnosis; stress: exposure to childhood maltreatment) 
are shown in Figure 1. The protective effect of being male (Figure 1A) and the risk from 
stress (Figure 1B) are consistent across the individual studies, and correspond to overall p-
values of 1.4E–15 and 1.7E–8, respectively. The lack of a main effect for the genetic variant 
in this model is also consistent across the studies (Figure 1C). For the interaction terms 
(childhood maltreatment exposure by number of S alleles) (Figure 1D), the point estimates 
are scattered on both sides of 1, and correspond to an overall p-value of 0.49.
Forest plots for these four key factors (sex, stress, gene, and gene × stress interaction) for the 
remaining analyses summarized in Table 1 are given in Supplemental Figures S1 through 
S5. Forest plots for the interaction terms for the remaining primary and secondary analyses 
are given in Supplemental Figures S6 to S14.
Our other primary analyses and additional secondary analyses examined questions of the 
strength, robustness, and conditions required to observe the hypothesized interaction. The 
results presented in Table 1 reflect the general consensus of the findings. None of the other 
primary analyses (results in Supplemental Tables S9 through S12) or secondary analyses 
(results in Supplemental Tables S13 through S16) resulted in a statistically significant 
interaction.
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We note that a closely related pair of young adult primary analyses resulted in nominally 
significant interactions (p-value < 0.05 before correction for multiple tests) in the 
hypothesized direction (Supplemental Table S10b). Several factors caution against placing 
too much confidence in these particular results: (i) failure of positive control – the point 
estimate for exposure to stress is protective for depression in these two analyses, counter to 
our more robust analyses and to what would be expected; (ii) they are not supported by 
closely related analyses – neither the matching analysis based on childhood maltreatment 
only, nor the other young adult analyses are even nominally significant (Tables S10b, S9, 
and S10a), and the matching analysis with subjects of all ages has the point estimates of 
effect in the opposite direction (Table S11b); (iii) statistical instability – these two analyses 
only include a small number of studies (3 and 4) with a relatively small total sample size 
(N=583 and N=1142), and are primarily driven by results from a single study; and (iv) 
neither p-value survives correction for the number of primary analyses performed.
Our protocol included secondary analyses to help determine whether analytic refinements 
might strengthen the result and explain why the hypothesized interaction had not heretofore 
been found consistently. To reduce heterogeneity in depression diagnosis, we examined the 
effect of restricting meta-analyses to depression diagnoses based on DSM or ICD criteria 
(Supplemental Table S13). To determine if the interaction might be predominantly expressed 
in only one sex, we performed meta-analyses stratified by sex (Supplemental Table S14). We 
examined alternative coding of the genetic effect (dominant, recessive, haplotype) 
(Supplemental Table S15). Because the question of causation depends on temporal order of 
events, we examined whether the interaction would be stronger if the analyses were 
restricted to data from longitudinal studies that had recorded temporal order (Supplemental 
Table S16). In each case, there is a trade-off between a possible gain in power due to a 
refined phenotype versus a loss in power due to smaller sample size. For these secondary 
analyses, we observed one nominally significant interaction in the opposite direction from 
the hypothesis (Supplemental Table S13, depression diagnosis restricted to DSM or ICD, 
broad stress, current depression, OR = 0.74, p = 0.01), and one nominally significant 
interaction in the hypothesized direction (Supplemental Table S15b), S allele coded as 
recessive, broad stress, lifetime depression, OR 1.25, p = 0.02). In all other analyses, the 
interaction term was not even nominally significant.
We evaluated the heterogeneity for the interaction terms in all the previous analyses. 
Supplemental Table S4 lists the I2 and Q heterogeneity statistics along with the p-value for 
the Q statistic for all the primary and secondary meta-analyses in the subsequent tables, 
demonstrating that there is generally little evidence for heterogeneity in these analyses. In 
particular, secondary analyses refining the diagnostic criteria and the study design did not 
substantially decrease the heterogeneity.
Cumulatively, these primary and secondary results exclude a strong, broadly generalizable 
interaction effect reported in Caspi et al. 2003.16
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DISCUSSION
A hallmark of science is the ability of results to be replicated, a criterion that has been 
increasingly recognized in biological and psychological research.66 The original 2003 report 
of an interaction between 5-HTTLPR genotype and stress exposure on depression16 has 
remained controversial due to inconsistent results from replication efforts. Although some 
researchers have claimed a replication of the hypothesized interaction based on different 
stressors, different measures of depression, or different genetic models,25, 26 other attempts 
to replicate the finding have been negative.23, 24, 67 The goal of our study was to rigorously 
explore the extent to which the original report could be replicated and generalized using a 
structured collaborative meta-analysis.
This is the largest study to date to use consistent statistical analyses across all samples to 
examine the hypothesized interaction between 5-HTTLPR genotype and stress exposure 
affecting major depression. As detailed in our protocol,1 our design was based on consistent, 
de novo analyses chosen by a consensus of participating researchers in the field, with 
inclusion open to all researchers with published or unpublished data that met objective 
minimum participation criteria. The purpose was to address multiple issues of concern about 
previous meta-analyses of the topic: (i) heterogeneity of phenotypes, (ii) publication bias 
from small studies, (iii) heterogeneity of statistical models used to produce the input for the 
meta-analysis, (iv) meta-analysis models that did not take direction of effect into account.
Neither our primary nor our secondary analyses found compelling evidence that the 5-
HTTLPR S allele increases risk of major depression in individuals exposed to stress. These 
results are in marked contrast to the robust main effect signals seen for the sex and stress 
exposure, where p-values less than 10−60 were seen in our most inclusive primary analyses 
(Supplemental Table S12). In our effort to determine conditions for which the interaction 
might be reliably detected, we investigated both childhood maltreatment and other life 
experiences as stressors. Because major depression is a recurring and remitting disease 
subject to recall bias, both current depression and lifetime depression were examined. Data 
from subjects of any age and data limited to young adults were both studied. We examined 
life stress known to precede depression (thereby limiting the sample to studies that 
documented the relative timing of stress and depression) and we investigated whether the 
hypothesized interaction could be more effectively detected using all available data with 
stress and depression assessed. In secondary analyses, we also examined multiple models for 
the coding of the genotype (additive, dominant, recessive, haplotypes) as well as broad and 
narrow requirements for documentation of temporal order of the stress experience and the 
onset of depression. Despite these efforts, we were unable to uncover specific subgroups 
where the G×E interaction was clearly expressed.
The Caspi group that originally proposed the hypothesis16 raised concerns regarding this 
meta-analysis project; in particular, the decisions to exclude small studies, and to include 
lifetime depression as an outcome for analysis were criticized.68 As noted in our methods, 
although we required studies to have at least 300 participants overall, inclusion in any 
particular meta-analysis required only 50 of these subjects to be genotyped and have the 
appropriate phenotypes (ancestry, depression outcome, covariates). Although Moffitt and 
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Caspi argue that small studies may be meticulously designed and have high quality data,68 
there is a case to be made that large studies are generally likely to have better design quality 
than small studies.69 In addition, small studies are subject to multiple statistical issues, 
including publication bias (exacerbated for small studies) and the winner’s curse (which 
makes it likely, even if a true effect is detected, that the magnitude will be exaggerated).70 In 
fact, a 2013 analysis of neuroscience publications concluded that small sample size studies 
were undermining the reliability of neuroscience.69
The concern Moffitt and Caspi raised regarding the inclusion of lifetime depression analyses 
was the difficulty of knowing the relative timing of stress and depression for a lifetime 
phenotype. Rather than omit these analyses of lifetime depression, as suggested by Moffitt 
and Caspi, we included analyses where timing information was specifically queried as well 
as analyses where it was not specifically queried. We recognize that these data, like all data, 
have limitations, but nonetheless we find the results informative. We note that of all the 
models examined in our de novo analyses, the only results with nominally significant 
interaction terms in the hypothesized direction were based on lifetime depression outcomes. 
Finally, based on parameter estimates provided in the supplement to their seminal paper,16 
we can estimate the impact those data would have on both our young adult and all-age 
analyses involving depression diagnoses with a quantitative life stress variable. We found 
that none of these analyses were nominally significant even after adding the Caspi et al. 
(2003) results to the meta-analyses.
The decision by some invited groups not to participate is a limitation of this project. It is 
becoming increasingly clear that large samples are an important tool for determining the role 
of genetic variation in complex phenotypes, such as depression. Combining existing data is 
an efficient tool for this purpose. We expect that in the future data sharing will become the 
rule rather than the exception. We are encouraged by the fact that data sharing is becoming a 
requirement of funding agencies and a requirement for publication by some journals. 
Although we would have preferred complete participation, several factors mitigate the 
impact that this likely had on our results. First, the phenotypes for several of the non-
participating groups turned out to be insufficient for inclusion in any of our primary or 
secondary analyses. Second, several of the non-participating groups had exclusively Asian 
samples, which would not have impacted the European ancestry results. Finally, we found 
that some data reported in the large prior meta-analyses as supportive of the interaction were 
not supportive when all were analyzed using the same statistical model for all studies.
Although our consortium tested many high-priority combinations of factors (see 
Supplemental Table S2), there remain other specific situations that we were unable to 
evaluate, such as limiting analyses to stress over a period shorter than five years, to financial 
stress,71 to persistent or recurrent depression,29, 72 or to childhood emotional abuse/neglect 
only.73 Using data from a diverse set of studies, most designed to address other questions, is 
also a limitation. However, we note that many of the participating studies, despite their 
diversity, have already been cited in the literature either in support of, or against, the 
hypothesized interaction.
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Our novel contribution is to apply a consistent methodology across the participating studies 
to query a broad range of questions about the hypothesized interaction. Although these 
studies remain varied in their original design, our unified approach to phenotype 
harmonization and statistical analysis has provided a sound and comprehensive exploration 
of this challenging question. We have addressed and excluded the major objections 
(exclusion of small studies, inclusion of analyses of lifetime depression) to our protocol 
raised by Caspi and Moffitt.
Our findings do not support the interaction hypothesis. We found no subgroups or variable 
definitions for which an interaction between stress and 5-HTTLPR genotype was 
statistically significant. In contrast, our findings for the main effects of sex (strong risk 
factor), life stressors (strong risk factor) and 5-HTTLPR genotype (no impact on risk) are 
strikingly consistent across the models examined in this study. Moreover, these robust main 
effect results are consistent with the main effect results from the Caspi study that originally 
reported the interaction,16 with the re-examination of the topic using primary data by Risch 
et al.,23 and with prior meta-analyses.23–26 Based on our findings, we conclude that if an 
interaction exists in which the S allele of 5-HTTLPR increases risk of depression only in 
stressed individuals, then it is not a broadly generalizable effect, but must be of modest 
effect size and only observable in limited situations. Our lack of replication coincides with 
findings of the Christchurch Health and Developmental Study,67 a prospective longitudinal 
birth-cohort, with measures, outcomes, and sample (both size and origin on the south island 
of New Zealand) nearly identical to the original report. This lack of evidence for a strong, 
robust effect should be taken into account before planning future research on this topic.
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Figure 1. 
Forest plots for lifetime depression diagnosis in subjects of all ages based on exposure to 
childhood maltreatment as the stressor
Depression = lifetime depression diagnosis (never depressed = 0; ever depressed = 1)
Sex (female = 0; male = 1)
Stress = childhood maltreatment (not exposed = 0; exposed = 1)
Gene (additive coding in number of S alleles for 5-HTTLPR (LL = 0; LS=1; SS=2))
1a. Sex: Being male consistently and significantly protects from a lifetime diagnosis of 
depression
1b. Stress: Exposure to stress consistently and significantly increases lifetime risk for 
depression
1c. Gene: The S allele (coded additively) is not associated with risk of lifetime depression
1d. Gene x Stress: Interaction term is not significant and does not suggest a consistent 
direction of effect across studies. (Hypothesized direction of effect: OR > 1)
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